Valbenazine free base | NBI-98854 | CAS#1025504-45-3 | CAS#1639208-54-0 | VMAT2 Inhibitor

MedKoo Cat#: 558280 | Name: Valbenazine free base

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Valbenazine, also known as NBI-98854 and MT-5199, is a potent and selective VMAT2 inhibitor. NBI-98854 is effective in regulating the levels of dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines. NBI-98854 is promising agent for the treatment of tardive dyskinesia.NBI-98854 significantly improved tardive dyskinesia and was well tolerated in patients. These results support the phase 3 clinical trials of NBI-98854 now underway.

Chemical Structure

Valbenazine free base

CAS#1025504-45-3 (free base)

Theoretical Analysis

MedKoo Cat#: 558280

Name: Valbenazine free base

CAS#: 1025504-45-3 (free base)

Chemical Formula: C24H38N2O4

Exact Mass: 418.2832

Molecular Weight: 418.58

Elemental Analysis: C, 68.87; H, 9.15; N, 6.69; O, 15.29

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 275.00	2 Weeks
50mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1025504-45-3 (free base) 1639208-54-0 (tosylate) 1639208-51-7 (2HCl)

Synonym

NBI-98854; NBI 98854; NBI98854; MT-5199; MT 5199; MT5199; Valbenazine; Ingrezza;

IUPAC/Chemical Name

(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate

InChi Key

GEJDGVNQKABXKG-CFKGEZKQSA-N

InChi Code

InChI=1S/C24H38N2O4/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3/t17-,19-,20-,23+/m1/s1

SMILES Code

N[C@@H](C(C)C)C(O[C@H]1[C@H](CC(C)C)CN2CCC3=CC(OC)=C(OC)C=C3[C@@]2([H])C1)=O

Appearance

White to off-white crystalline powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# 1025504-45-3 (Valbenazine free base) 1639208-54-0 (Valbenazine tartrate) 1639208-51-7 (Valbenazine dihydrochloride)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 418.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Terry-Lorenzo R, Albrecht D, Crouch S, Wong R, Loewen G, Giri N, Skor H, Lin K, Sandiego CM, Pajonas M, Rabiner EA, Gunn RN, Russell DS, Haubenberger D. Correction: Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study. Neuropsychopharmacology. 2025 Jan 22. doi: 10.1038/s41386-025-02055-w. Epub ahead of print. Erratum for: Neuropsychopharmacology. 2025 Jan 5. doi: 10.1038/s41386-024-02046-3. PMID: 39843851. 2: Frank S, Testa CM, Goldstein J, Kayson E, Leavitt BR, Oakes D, O'Neill C, Whaley J, Gross N, Chaijale N, Barash S, Gordon MF; Huntington Study Group/ARC- HD Investigators and Coordinators. Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease. CNS Drugs. 2025 Feb;39(2):185-195. doi: 10.1007/s40263-024-01139-3. Epub 2025 Jan 18. PMID: 39825184; PMCID: PMC11769868. 3: Kane M. Valbenazine Therapy and CYP2D6 Genotype. 2024 Nov 13 [updated 2025 Jan 17]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. PMID: 39565887. 4: Terry-Lorenzo R, Albrecht D, Crouch S, Wong R, Loewen G, Giri N, Skor H, Lin K, Sandiego CM, Pajonas M, Rabiner EA, Gunn RN, Russell DS, Haubenberger D. Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study. Neuropsychopharmacology. 2025 Jan 5. doi: 10.1038/s41386-024-02046-3. Epub ahead of print. Erratum in: Neuropsychopharmacology. 2025 Jan 22. doi: 10.1038/s41386-025-02055-w. PMID: 39757283. 5: Wei F, Liu H, Zhang W, Wang J, Zhang Y. Drug inhibition and substrate transport mechanisms of human VMAT2. Nat Commun. 2025 Jan 2;16(1):323. doi: 10.1038/s41467-024-55361-0. PMID: 39747030; PMCID: PMC11695631. 6: Patino J, Furr Stimming E, Testa CM, Mehanna R. Valbenazine for the treatment of chorea associated with Huntington's disease. Expert Opin Pharmacother. 2025 Feb;26(2):127-132. doi: 10.1080/14656566.2024.2445728. Epub 2024 Dec 30. PMID: 39729631. 7: Solmi M, Fornaro M, Caiolo S, Lussignoli M, Caiazza C, De Prisco M, Solini N, de Bartolomeis A, Iasevoli F, Pigato G, Del Giovane C, Cipriani A, Correll CU. Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis. Mol Psychiatry. 2024 Dec 18. doi: 10.1038/s41380-024-02733-z. Epub ahead of print. PMID: 39695322. 8: Neeman J, Lang SE, Jiao J. Suicidal Ideation and Self-harming Thoughts With Valbenazine Use: A Case Report. J Clin Psychopharmacol. 2024 Nov- Dec;44(6):596-598. doi: 10.1097/JCP.0000000000001920. PMID: 39514299. 9: Irinaka K, Itoh Y, Yoshizawa K, Ogasawara M, Ayabe N, Mishima K, Takeshima M. Successful Electroconvulsive Therapy for Tardive Dyskinesia and Tardive Dystonia Refractory to Valbenazine Treatment: A Case Report and Narrative Literature Review. Clin Psychopharmacol Neurosci. 2024 Nov 30;22(4):688-696. doi: 10.9758/cpn.24.1185. Epub 2024 Aug 7. PMID: 39420617; PMCID: PMC11494429. 10: Ma E, Krening E, Bruno MK. Dissemination of VMAT-2 Inhibitors: A New Class Drug for Tardive Dyskinesia and Huntington Disease. Neurol Clin Pract. 2025 Feb;15(1):e200392. doi: 10.1212/CPJ.0000000000200392. Epub 2024 Oct 8. PMID: 39399570; PMCID: PMC11464224. 11: Richards K, Johnsrud M, Zacker C, Sasané R. Detailing Healthcare Claims Data Evidence of Extrapyramidal Symptoms in Medicaid Patients with Schizophrenia after Second-Generation Antipsychotic Medication Initiation. Community Ment Health J. 2024 Sep 6. doi: 10.1007/s10597-024-01347-7. Epub ahead of print. PMID: 39240484. 12: Mulla WE. Atypical Antipsychotic-Induced Tardive Dyskinesia in a Middle-Aged Schizophrenic Patient: A Case Report. Cureus. 2024 Jul 29;16(7):e65663. doi: 10.7759/cureus.65663. PMID: 39205717; PMCID: PMC11353551. 13: Watanabe Y, Susuta Y, Nagano M, Masui H, Kanahara N. Efficacy and Safety of Valbenazine in Elderly and Nonelderly Japanese Patients With Tardive Dyskinesia: A Post Hoc Analysis of the J-KINECT Study. J Clin Psychopharmacol. 2024 Nov- Dec;44(6):551-560. doi: 10.1097/JCP.0000000000001903. Epub 2024 Aug 27. PMID: 39186921. 14: Nguyen HQ, Kuan HS, Crass RL, Quinlan L, Chapel S, Kim K, Brar S, Loewen G. A Model-Informed Drug Development Approach Supporting the Approval of an Unstudied Valbenazine Dose for Patients With Tardive Dyskinesia. J Clin Pharmacol. 2024 Nov;64(11):1456-1465. doi: 10.1002/jcph.2498. Epub 2024 Jul 25. PMID: 39051716. 15: Ismail O, Albdour K, Jaber Y, Jaber K, Alsaras A. Efficacy and safety of different pharmacological interventions in the treatment of tardive dyskinesia: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2024 Oct;80(10):1471-1482. doi: 10.1007/s00228-024-03722-5. Epub 2024 Jul 6. PMID: 38969949. 16: Zhang Y, Jia X, Shi X, Chen Y, Xue M, Shen G, Wen L, Qiao Y, Yang Y. Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system. Gen Hosp Psychiatry. 2024 Sep-Oct;90:22-29. doi: 10.1016/j.genhosppsych.2024.06.005. Epub 2024 Jun 12. PMID: 38901166. 17: Besag FMC, Vasey MJ, Salim I, Hollis C. Tardive Dyskinesia with Antipsychotic Medication in Children and Adolescents: A Systematic Literature Review. Drug Saf. 2024 Nov;47(11):1095-1126. doi: 10.1007/s40264-024-01446-0. Epub 2024 Jun 11. PMID: 38862692. 18: Correll CU, Citrome L, Singer C, Lindenmayer JP, Zinger C, Liang G, Dunayevich E, Marder SR. Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients With Tardive Dyskinesia. J Clin Psychopharmacol. 2024 Jul-Aug 01;44(4):353-361. doi: 10.1097/JCP.0000000000001860. Epub 2024 May 20. PMID: 38767901. 19: Adelakun AA, Choi C, Brensilver J. Severe Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Following the Initiation of Valbenazine for Tardive Dyskinesia: A Case Report. Cureus. 2024 Apr 17;16(4):e58493. doi: 10.7759/cureus.58493. PMID: 38765393; PMCID: PMC11101299. 20: Wong S, Le GH, Kwan ATH, Rhee TG, Teopiz KM, Ho RC, Cao B, Rosenblat JD, Mansur R, McIntyre RS. Risk of VMAT2 inhibitors on suicidality and parkinsonism: report utilizing the United States Food and Drug Administration adverse event reporting system. Int Clin Psychopharmacol. 2024 May 11. doi: 10.1097/YIC.0000000000000553. Epub ahead of print. PMID: 38727416.